



AR: COVID-19 Emergency Response Project (P173767)

LATIN AMERICA AND CARIBBEAN | Argentina | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 5 | ARCHIVED on 22-Jun-2022 | ISR50818 |

Implementing Agencies: Argentine Republic, National Ministry of Health

Key Dates

Key Project Dates

Bank Approval Date: 02-Apr-2020

Effectiveness Date: 07-May-2020

Planned Mid Term Review Date: 30-Sep-2022

Actual Mid-Term Review Date: 30-Mar-2022

Original Closing Date: 29-Apr-2022

Revised Closing Date: 30-Apr-2024

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To strengthen preparedness and response efforts against the COVID-19 pandemic and national systems for public health preparedness in Argentina

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name
Emergency COVID-19 Response Efforts:(Cost \$532.90 M)
Implementation, Monitoring and Evaluation:(Cost \$2.10 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Risk Rating	<input type="checkbox"/> High	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

The Argentina COVID-19 Emergency Response Project was approved by the WB Board of Directors on April 2, 2020 with the objective of strengthening the national health system for emergency preparedness and response to COVID-19 pandemic in an amount of US\$ 35 million. This Project is part of a World Bank Multi-Phase Programmatic Approach to support countries affected by the COVID-19 pandemic. The Project was declared effective on May 7, 2020. As of May 31, 2021 all project activities were implemented and the Project's funds are hundred percent disbursed.

On September 30, the Board approved an Additional Financing Loan (AF) in an amount of US\$ 500 million mainly to support the financing of vaccines. The AF Loan was declared effective on October 6, 2021. As of May 31, 2022 all project activities are under implementation and the Project is 99.6 percent disbursed.



MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

As of June 15, 2022, 88 MPA-projects had been approved with a total commitment of US\$4.3 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. Six parent projects have been restructured to include vaccine-related procurement. **Total disbursements as of June 15, 2022, amount to US\$3.6 billion or 84% of overall commitments.** This amount does not include disbursements under MPA-V operations which are reported together with AF-V operations. **Sixty-seven (67) country projects or 77% of projects approved have reached 70-100% disbursement** (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). **Out of the 67 operations, 48 operations or 72% have disbursed over 90% of commitments. Of these, 30 operations are fully disbursed. There are thirteen (13) operations with closing dates by the end of FY22. Other 10 operations which had closing dates by the end of the FY have extended their closing dates. There are 12 operations with disbursements under 50%. Out of these 12 operations, one has not disbursed, and four have disbursed 30 percent or less.** The projects are benefitting around 3.7 billion people or 50% of the global population. Of the 87 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 8 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-six (86) or 99% of projects approved are disbursing. MNA has the highest percentage of disbursements, followed by SRA, EAP, ECA and LAC, AFE and AFW. Retroactive Financing represents 26% of commitments. **Country teams for operations, which have been under implementation for twelve months or more by June 30, 2022, are preparing Mid-Term Review (MTR) ISRs to inform the Global MPA MTR, which will be prepared early next FY.**

Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Implementation continues to face challenges as several countries are still under different levels of mobility restrictions. Bank staff are operating in a hybrid environment with some days at the office and others at home. Notwithstanding the challenges, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements attests to the strong implementation of the Bank' response thanks to the commitment of counterparts supported by Bank country teams.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach ("Global COVID-19 MPA") was approved by the Board on October 13, 2021. The AF-V is significantly expanding Bank support to client countries for COVID-19 vaccination, with the aim to support vaccination of 1 billion people globally. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. **On June 30, 2021, President Malpass announced the expansion of financing available for COVID-19 vaccine financing to \$20 billion over the next 18 months, adding \$8 billion to the previously announced \$12 billion.** This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG's overall COVID-19 response.

As of June 15, 2022, the Bank has approved 105 operations (including MPA-V operations) to support vaccine procurement and rollout in 77 countries amounting to \$9.6 billion. The 105 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 105



approved operations: (i) 56 are in Africa – 26 in AFE and 30 in AFW; (ii) 9 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. Fifty-three (53) projects are disbursing. **Total disbursements as of June 15, 2022, under these projects amount to US\$3.4 billion or 35% of overall commitments. Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. Sixteen (16) operations have disbursed over 70% of their commitments. Out of the 16, seven have disbursed 90%. Retroactive Financing represents 44% of overall commitments.** Thirteen (13) new operations are under various stages of processing. As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Eighty-eight (88) loan/financing agreements have been signed. Also, eighty-six (86) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of mobility restrictions and counterparts and Bank teams are operating in a hybrid environment with some days at the office and some at home. Countries are dealing with new waves of infections, as the Omicron variant continues to spread rapidly among populations.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	☐ Moderate	☐ Moderate	☐ Moderate
Macroeconomic	☐ High	☐ Substantial	☐ Substantial
Sector Strategies and Policies	☐ Moderate	☐ Moderate	☐ Moderate
Technical Design of Project or Program	☐ Substantial	☐ High	☐ Substantial
Institutional Capacity for Implementation and Sustainability	☐ Substantial	☐ Substantial	☐ Substantial
Fiduciary	☐ Moderate	☐ Substantial	☐ Moderate
Environment and Social	☐ Moderate	☐ Substantial	☐ Substantial
Stakeholders	☐ Low	☐ Low	☐ Low
Other	--	--	--
Overall	☐ Substantial	☐ High	☐ Substantial

Results

PDO Indicators by Objectives / Outcomes

Support detection and response efforts in the fight against COVID-19

► Percentage of suspected cases of COVID-19 reported and investigated per approved protocols (Percentage, Custom)

Baseline

Actual (Previous)

Actual (Current)

End Target



Value	0.00	91.34	94.70	90.00
Date	28-Feb-2020	02-Jun-2021	28-Feb-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Percentage of diagnosed cases treated per approved protocols (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	99.85	100.00	90.00
Date	28-Feb-2020	02-Jun-2021	28-Feb-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Percentage of acute healthcare facilities with increased isolation capacity (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	80.00
Date	28-Feb-2020	28-May-2021	28-Feb-2022	31-Dec-2021
► Percentage of population vaccinated, which is included in the priority population targets, as defined in the NSVP for the Introduction of the Vaccine against COVID-19 (disaggregated by sex) (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	31.80	32.70
Date	30-Jun-2021	30-Jun-2021	31-Mar-2022	29-Dec-2023
► Percentage of female population vaccinated, which is included in the priority population targets, as defined in the NSVP for the Introduction of the Vaccine against COVID-19 (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	32.80	32.70
Date	30-Jun-2021	30-Jun-2021	31-Mar-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			

Intermediate Results Indicators by Components

Emergency COVID-19 Response Efforts
► Number of laboratories conducting COVID-19 sample testing (Number, Custom)



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	34.00	35.00	24.00
Date	28-Feb-2020	28-May-2021	28-Feb-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Percentage of public hospitals with Intensive Care Units strengthened (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	72.50	72.49	90.00
Date	28-Feb-2020	28-May-2021	31-Mar-2022	31-Dec-2021
► Percentage of public hospitals with Intensive Care Units that received training according approved protocols (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	87.00	87.00	80.00
Date	28-Feb-2020	28-May-2021	31-Dec-2021	29-Dec-2023
Comments:	End- Project Target has been achieved			
► Percentage of participating hospitals with personal protective equipment and infection control products and supplies, provided (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	74.60	74.67	90.00
Date	28-Feb-2020	28-May-2021	31-Mar-2022	31-Dec-2021
► AR COVID-19 Fatality Rate (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	2.10	1.40	2.50
Date	28-Feb-2020	01-Jun-2021	28-Feb-2022	29-Dec-2023
► Provincial Emergency Committees with multisectoral participation, including civil society organizations, created and operational” (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	70.80	70.83	70.00
Date	19-Mar-2020	28-May-2021	31-Dec-2021	29-Dec-2023
Comments:	Percentage of provinces that implement an Emergency Committees (COE) since the beginning of the pandemic, according to the guidelines of the Ministry of Health (MoH) with the participation of Civil Society Organizations (SCO) and/or private health sector representatives.			



End- Project target has been achieved.				
► Number of doses of COVID-19 vaccine procured with Project funding (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	30,026,331.00	30,000,000.00
Date	30-Jun-2021	30-Jun-2021	31-Mar-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Health staff trained in COVID-19 vaccination process according to protocols approved by the NMOH (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	5,000.00	5,000.00	7,336.00	10,000.00
Date	30-Jun-2021	30-Jun-2021	28-Feb-2022	29-Dec-2023
► Percentage of provinces with updated vaccination plans to implement the NSVP against COVID-19 (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	100.00	90.00
Date	30-Jun-2021	30-Jun-2021	31-Dec-2021	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Updated health management and information system to deploy a Pharmacovigilance strategy of AEFIs for COVID-19 vaccination with new guidelines according the NSVP and NMOH technical guidelines (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	Yes	Yes
Date	30-Jun-2021	30-Jun-2021	31-Mar-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			
► New Communication strategies developed and disseminated in support of the NSVP (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	Yes	Yes
Date	30-Jun-2021	30-Jun-2021	31-Mar-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			



► Share of women vaccinated against COVID-19 with at least one dose in the Northeastern region, in line with national average (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	51.00	55.00	73.00	59.00
Date	03-Aug-2021	23-Aug-2021	31-Mar-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Share of women trained as vaccinators (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	50.00	50.00	79.00	60.00
Date	30-Jun-2021	30-Jun-2021	31-Dec-2021	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Share of female workers responsible for COVID-19 vaccination campaigns in Expanded Programs on Immunization (EPI) throughout the country (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	45.00	45.00	79.00	50.00
Date	30-Jun-2021	30-Jun-2021	28-Feb-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			
► Population fully vaccinated included in the priority population targets defined in the NSVP and NMOH technical guidelines (total and disaggregated by sex) (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	14.00	14.00	80.00	70.00
Date	30-Jun-2021	30-Jun-2021	31-Mar-2022	29-Dec-2023
Comments:	End- Project target has been achieved.			

Performance-Based Conditions

Data on Financial Performance

Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
---------	----------------	--------	----------	----------	---------	-----------	-----------	-------------	-------------




P173767	IBRD-90830	Closed	USD	35.00	35.00	0.00	35.00	0.00	<div style="width: 100%; height: 10px; background-color: green;"></div>	100%
P173767	IBRD-92920	Effective	USD	500.00	500.00	0.00	498.00	2.00	<div style="width: 100%; height: 10px; background-color: green;"></div>	100%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173767	IBRD-90830	Closed	02-Apr-2020	05-May-2020	07-May-2020	29-Apr-2022	29-Apr-2022
P173767	IBRD-92920	Effective	30-Sep-2021	04-Oct-2021	06-Oct-2021	30-Apr-2024	30-Apr-2024

Cumulative Disbursements



Restructuring History

There has been no restructuring to date.

Related Project(s)

P177246-Additional Financing for the Argentina: COVID-19 Emergency Response Project